Inovio Pharmaceuticals In... (INO)
| Bid | 1.58 |
| Market Cap | 58.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.95 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -0.71 |
| Analyst | Buy |
| Ask | 1.6 |
| Volume | 576,819 |
| Avg. Volume (20D) | 853,765 |
| Open | 1.63 |
| Previous Close | 1.66 |
| Day's Range | 1.53 - 1.61 |
| 52-Week Range | 1.47 - 13.44 |
| Beta | 0.92 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery o...
Analyst Forecast
According to 6 analyst ratings, the average rating for INO stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 934.48% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call TranscriptInovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical...
